NICE draft guidance recommends apalutamide for treating prostate cancer

NICE

8 September 2021 - NICE has today published final draft guidance which now recommends apalutamide (Erleada; Janssen) plus androgen deprivation therapy for treating prostate cancer in adults.

The positive recommendations follow an improved discount to the price of apalutamide offered by Janssen.

Read NICE press release

Michael Wonder

Posted by:

Michael Wonder